CAI

Caris Life Sciences, Inc. (CAI) - 10-Q Summary for Period Ended June 30, 2025

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the three and six months ended June 30, 2025. Caris Life Sciences, Inc. is a patient-centric, AI-driven TechBio company focused on precision oncology. The reporting period is defined by a major corporate transition: the Company completed its Initial Public Offering (IPO) on June 20, 2025, at a price of $21.00 per share. Consequently, all outstanding redeemable convertible preferred stock and certain convertible notes converted into common stock during the quarter. The Company operates as a single segment, providing molecular profiling services (MI Profile, Caris Assure) and pharma research and development services.

Key Financial Metrics

Note: Net Loss Attributable to Common Shareholders includes a non-cash deemed dividend of $384.4 million related to the conversion of Series D preferred stock triggered by the IPO.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 81.3% year-over-year for the quarter and 67.3% for the six-month period. Molecular profiling services revenue grew 85.9% (QoQ) and 72.2% (6-month), driven by higher Average Selling Prices (ASP) from the launch of MI Cancer Seek and increased clinical case volumes (up 22.0% in the quarter).
• Expense Increases: General and Administrative (G&A) expenses surged 56.7% for the quarter, primarily due to a $20.3 million increase in stock-based compensation expense linked to IPO-related vesting conditions. Research and Development (R&D) expenses remained relatively flat for the quarter but decreased 18.7% for the six-month period due to reduced material costs.
• Non-GAAP Performance: The Company achieved positive Adjusted EBITDA of $16.7 million for the quarter, compared to a loss of $(50.9) million in the prior year quarter, reflecting improved operational leverage despite the IPO-related expenses.
• Liquidity Transformation: Cash and cash equivalents increased from $65.4 million at year-end 2024 to $720.4 million at June 30, 2025, following the IPO which generated net proceeds of approximately $528.5 million.

Guidance, Outlook, and Risks

Outlook and Commentary: Management expects continued growth driven by the adoption of MI Cancer Seek and the expansion of Caris Assure into early detection and minimal residual disease (MRD) tracking. The Company plans to utilize IPO proceeds to fund operations, expand laboratory capacity in Irving, Texas, and invest in R&D. No specific numerical guidance for future periods was provided in this filing.

Material Risks and Contingencies:

• Internal Controls: The Company disclosed a material weakness in internal control over financial reporting related to a lack of sufficient qualified accounting resources. Remediation efforts are ongoing, but the weakness was not fully remediated as of June 30, 2025.
• Legal Proceedings: In March 2025, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding compliance with Medicare's "14-day rule" under the False Claims Act. The investigation is ongoing, and outcomes are uncertain.
• Regulatory Uncertainty: The Company faces uncertainty regarding the regulation of Laboratory Developed Tests (LDTs) by the FDA, which could impact the commercialization of current and future solutions.
• Debt Obligations: The Company has $400.0 million in outstanding variable-rate debt under a 2023 Term Loan, subject to interest rate risk and restrictive covenants.

Investor Verification Checklist

• Deemed Dividend Impact: Verify the impact of the $384.4 million non-cash deemed dividend on Net Loss Attributable to Common Shareholders to understand the true operating loss versus accounting adjustments.
• Internal Control Remediation: Monitor the progress of remediation for the material weakness in internal controls, as this affects the reliability of future financial reporting.
• DOJ Investigation Status: Track the status of the DOJ investigation regarding the Medicare 14-day rule, as a negative outcome could result in significant penalties or recoupments.
• Reimbursement Trends: Analyze the sustainability of the increased Average Selling Price (ASP) for MI Profile and the reimbursement rates for Caris Assure, given the competitive payer landscape.
• Debt Service Capacity: Assess the Company's ability to service its $400 million variable-rate debt given the current interest rate environment and the Company's path to sustained profitability.